Generate Biomedicines, Inc. GENB Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

ConstelliumCSTM

$2M0.0%

PopularBPOP

$2.03M+124%

SeaboardSEB

$8M-20.0%

Churchill DownsCHDN

$725K+11.5%

Cavco IndustriesCVCO

$89K+33.3%

Equinix, Inc.EQIX

$41M+28.1%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's finance lease, principal payments?: Generate Biomedicines, Inc. (GENB) reported finance lease, principal payments of $1.12M in Q1 2026.